Veru Inc. to Engage with Investors at BTIG Obesity Health Forum on June 18, 2025

Veru Inc. (VERU) will present at the BTIG Obesity Health Forum on June 18, 2025, highlighting its focus on cardiometabolic and inflammatory disease treatments. The company reported positive Phase 2b results for enobosarm, aimed at enhancing fat loss and preserving muscle mass in older adults using semaglutide, and plans to request an End of Phase 2 meeting with the FDA. Veru is also exploring sabizabulin, an anti-inflammatory agent, for treating inflammation in atherosclerotic cardiovascular disease, with plans to submit an IND application by mid-2026.

Analysis

Veru Inc. is advancing its cardiometabolic and inflammatory disease pipeline, highlighted by its upcoming participation in the BTIG Obesity Health Forum on June 18, 2025. The company has reported positive topline and safety results from its Phase 2b QUALITY clinical trial for enobosarm, a selective androgen receptor modulator designed to augment fat loss and preserve muscle mass in older patients concurrently using semaglutide for weight management; an End of Phase 2 meeting with the FDA has been requested, signaling progress towards later-stage development. Topline results from a Phase 2b extension study, evaluating enobosarm's potential to prevent fat regain post-GLP-1 RA cessation, are anticipated in Q2 2025. Concurrently, Veru is strategically exploring sabizabulin, an anti-inflammatory agent with existing safety data from 266 patients in prior studies, for the treatment of inflammation in atherosclerotic cardiovascular disease (ASCVD), a significant unmet medical need. The company plans an Investigational New Drug (IND) submission for sabizabulin in this indication by mid-2026, supported by preclinical data demonstrating broad anti-inflammatory efficacy. Positive insider activity, with Michael L. Rankowitz purchasing 150,000 shares for approximately $84,350 in the last six months, contrasts with mixed institutional holdings. Notably, several large institutional investors, including Perceptive Advisors LLC and Millennium Management LLC, liquidated their entire positions or significantly reduced their stakes in Q1 2025, while others like MPM Bioimpact LLC and UBS Group AG initiated or substantially increased their holdings. This divergence warrants attention, alongside the inherent uncertainties associated with forward-looking statements and clinical trial timelines common in biopharmaceutical development.

Key Decisions for Investors

• Investors should recognize the potential of enobosarm, given its positive Phase 2b data and strategic positioning to complement the GLP-1 receptor agonist market by addressing muscle loss, while closely monitoring the Q2 2025 extension study results and FDA feedback.
• The development of sabizabulin for atherosclerotic cardiovascular disease represents a significant market opportunity; however, its progression is contingent on successful preclinical toxicology studies and an IND submission planned for H1 2026, requiring patience and scrutiny of interim updates.
• Consider the conflicting signals from recent insider purchases, which suggest management confidence, against substantial divestitures by several large institutional funds, and evaluate risk tolerance in light of upcoming clinical and regulatory catalysts for this late-stage biopharmaceutical company.
• Maintain awareness of the risks detailed in Veru's forward-looking statements, including potential clinical trial delays and the substantial capital typically required for Phase 3 trials and commercialization, which may impact future financing needs.